Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Eric_Kelsic
|
| gptkbp:collaboratedWith |
gptkb:Sarepta_Therapeutics
gptkb:Novartis gptkb:Roche |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
gene therapy
AAV capsid engineering |
| gptkbp:foundedIn |
2018
|
| gptkbp:founder |
gptkb:Eric_Kelsic
gptkb:George_Church |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dyno Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableFor |
machine learning-driven gene therapy vectors
|
| gptkbp:specializesIn |
AAV vector design
|
| gptkbp:technology |
gptkb:artificial_intelligence
|
| gptkbp:website |
https://www.dynotx.com/
|
| gptkbp:bfsParent |
gptkb:George_Church
|
| gptkbp:bfsLayer |
5
|